Tumor News and Research

RSS

Researchers identify molecular pathway that may play key role in evolution of chemotherapy resistance

For patients with ovarian cancer and their physicians, resistance to chemotherapy is a serious concern. However, researchers at Moffitt Cancer Center have identified a molecular pathway that may play a key role in the evolution of chemotherapy resistance.

16 Sep 2011

Researchers identify promising new therapies for ependymoma

Researchers have identified promising new therapies for ependymoma, a rare tumor with few treatment options. St. Jude Children's Research Hospital investigators led the effort, which used a new, faster drug development system that combines the latest drug screening technology with the first accurate animal model of the tumor.

16 Sep 2011

New GE healthymagination initiative aims to improve cancer innovation and care

GE and leading healthcare and financial partners today launched a new healthymagination initiative aimed at accelerating cancer innovation and improving care for 10 million cancer patients around the world by 2020.

16 Sep 2011

Polyplus-transfection appoints ten additional biologists and chemists to support multiple pre-clinical studies

Polyplus-transfection SA, which specializes in the development of innovative solutions for the delivery of nucleic acids in research and therapeutics, today celebrates ten years of continuous growth.

15 Sep 2011

NCCN 6th annual congress discusses role of maintenance therapies in follicular lymphoma

While therapeutic advances have improved survival of patients with follicular lymphoma (FL), it remains an incurable disease with inevitable relapse. This underscores the need for therapies and strategies to extend the duration of remission without significantly increasing toxicity and while maintaining quality of life.

15 Sep 2011

Differences in lifestyle, tumor genetics linked to head and neck cancer in African Americans

Why are African Americans more likely than Caucasians to be not only diagnosed with head and neck cancer, but also die from the disease? While the answer isn't a simple one, differences in lifestyle, access to care and tumor genetics may, in part, be to blame, according to a new study from Henry Ford Hospital.

15 Sep 2011

Glucose metabolism inhibition with 2-DG induces cell death in alveolar rhabdomyosarcoma

A study made by IDIBELL researchers shows that glucose metabolism inhibition with 2-deoxyglucose (2-DG) induces cell death in a type of childhood sarcoma: alveolar rhabdomyosarcoma.

15 Sep 2011

Celecoxib inhibits GSK3 enzyme in lung cancer cells

Several clinical studies have shown that taking the anti-inflammatory drug celecoxib can reduce the risk of developing polyps that lead to colon cancers, at the cost of increasing the risk of heart disease. But what if this tradeoff was not necessary?

14 Sep 2011

STED microscope reveals that F-actin pervades immunological synapse

Making use of a new "super resolution" microscope that provides sharp images at extremely small scales, scientists have achieved unprecedented views of the immune system in action.

14 Sep 2011

BVES protein may play a role in colon cancer progression

A protein critical in heart development may also play a part in colon cancer progression. Research led by investigators from Vanderbilt-Ingram Cancer Center and the Vanderbilt Eye Institute suggests that the protein BVES (blood vessel endocardial substance) - which also is key in regulating corneal cells - may be a therapeutic target for halting colon cancer metastasis.

14 Sep 2011

Scientists decode new mechanism that regulates cell polarity in epithelial tissues, neurons

In the course of examining the Drosophila tumor suppressor gene (Dlg), scientists at the Helmholtz Zentrum München have succeeded in decoding a new mechanism that regulates cell polarity in epithelial tissues or in neurons in the brain.

14 Sep 2011

Natural S-equol supplement does not increase risk of estrogen-sensitive breast cancer

Consuming the soy germ-based compound Natural S-equol and the supplement SE5-OH containing Natural S-equol did not increase the risk of estrogen-sensitive breast cancer, according to a study in the September issue of the peer-reviewed journal Food and Chemical Toxicology.

14 Sep 2011

Nanobiotix starts clinical trial of new cancer treatment for soft tissue sarcoma

Nanobiotix, a company developing novel cancer nanotherapeutics, announced today that its lead compound NBTXR3 has received the formal authorization from the French Medicine Agency, AFSSAPS, to start the first clinical trial.

14 Sep 2011

Efficient, economical molecule could speed evaluation of some anti-cancer treatments

Researchers from Boston College have developed a new class of small molecule receptors capable of detecting a lipid molecule that reveals the telltale signs of cellular death, particularly cancer cells targeted by anti-cancer drugs, the team reports in the current electronic edition of the Journal of the American Chemical Society.

14 Sep 2011

OBT, Seattle Genetics form strategic collaboration to discover novel ADCs for cancer

Seattle Genetics, Inc. and Oxford BioTherapeutics today announced that they have formed a strategic collaboration to jointly discover novel antibody-drug conjugates (ADCs) for cancer.

14 Sep 2011

Henry Ford study identifies 23 microRNAs for laryngeal cancer

A Henry Ford Hospital study has identified 23 microRNAs for laryngeal cancer, a discovery that could yield new insight into what causes certain cells to grow and become cancerous tumors in the voice box.

14 Sep 2011

FDA announces organizational changes within CDER's Office of Oncology Drug Products

Today, the U.S. Food and Drug Administration announced organizational changes within the office responsible for reviewing all drug and biologic applications for cancer therapies.

13 Sep 2011

New drug combination may treat two aggressive cancers

Researchers at Brigham and Women's Hospital (BWH) have identified a new combination of targeted therapies that, together, may treat two aggressive tumor types that until now have not had effective treatments. These findings are published in Cancer Cell on September 13, 2011.

13 Sep 2011

Delcath announces updated Phase 2 trial results from metastatic neuroendocrine tumor cohort

Delcath Systems, Inc. announced that updated results from the metastatic neuroendocrine tumor (mNET) cohort of the Company's recently completed Phase 2 clinical trial were presented at the Cardiovascular and Interventional Radiological Society of Europe (CIRSE) congress held this week in Munich, Germany.

13 Sep 2011

Researchers identify new type of potential anticancer drug

Researchers at Emory University School of Medicine have identified a new type of potential anticancer drug. The compound, named FOBISIN, targets 14-3-3 proteins, important for the runaway growth of cancer cells.

13 Sep 2011

Tumor News and Research

Researchers identify molecular pathway that may play key role in evolution of chemotherapy resistance

Researchers identify promising new therapies for ependymoma

New GE healthymagination initiative aims to improve cancer innovation and care

Polyplus-transfection appoints ten additional biologists and chemists to support multiple pre-clinical studies

NCCN 6th annual congress discusses role of maintenance therapies in follicular lymphoma

Differences in lifestyle, tumor genetics linked to head and neck cancer in African Americans

Glucose metabolism inhibition with 2-DG induces cell death in alveolar rhabdomyosarcoma

Celecoxib inhibits GSK3 enzyme in lung cancer cells

STED microscope reveals that F-actin pervades immunological synapse

BVES protein may play a role in colon cancer progression

Scientists decode new mechanism that regulates cell polarity in epithelial tissues, neurons

Natural S-equol supplement does not increase risk of estrogen-sensitive breast cancer

Nanobiotix starts clinical trial of new cancer treatment for soft tissue sarcoma

Efficient, economical molecule could speed evaluation of some anti-cancer treatments

OBT, Seattle Genetics form strategic collaboration to discover novel ADCs for cancer

Henry Ford study identifies 23 microRNAs for laryngeal cancer

FDA announces organizational changes within CDER's Office of Oncology Drug Products

New drug combination may treat two aggressive cancers

Delcath announces updated Phase 2 trial results from metastatic neuroendocrine tumor cohort

Researchers identify new type of potential anticancer drug

Industry Focus eBook - Cell & Gene Therapy (1st Edition) eBook

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Expanding access to NMR with the Fourier 80 Duo

Latest News